Algert Global LLC Sells 6,580 Shares of MaxCyte, Inc. (NASDAQ:MXCT)

Algert Global LLC cut its holdings in shares of MaxCyte, Inc. (NASDAQ:MXCT) by 3.1% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 202,435 shares of the company’s stock after selling 6,580 shares during the period. Algert Global LLC owned about 0.19% of MaxCyte worth $794,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Cadian Capital Management LP acquired a new position in MaxCyte in the fourth quarter worth $26,531,000. Vanguard Group Inc. grew its holdings in MaxCyte by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 5,347,112 shares of the company’s stock worth $22,404,000 after acquiring an additional 65,004 shares during the last quarter. River Global Investors LLP grew its holdings in MaxCyte by 24.4% during the 1st quarter. River Global Investors LLP now owns 1,888,642 shares of the company’s stock worth $7,973,000 after acquiring an additional 369,996 shares during the last quarter. Swedbank AB acquired a new stake in MaxCyte in the 1st quarter valued at about $6,704,000. Finally, Chevy Chase Trust Holdings LLC raised its stake in shares of MaxCyte by 2.0% in the second quarter. Chevy Chase Trust Holdings LLC now owns 1,322,560 shares of the company’s stock worth $5,184,000 after acquiring an additional 26,163 shares during the last quarter. 68.81% of the stock is owned by institutional investors and hedge funds.

Insider Activity at MaxCyte

In related news, Director Stanley C. Erck sold 21,607 shares of the firm’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $3.71, for a total value of $80,161.97. Following the transaction, the director now owns 269,118 shares in the company, valued at $998,427.78. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, EVP Thomas M. Ross sold 13,531 shares of the firm’s stock in a transaction dated Tuesday, July 9th. The stock was sold at an average price of $4.03, for a total value of $54,529.93. Following the transaction, the executive vice president now owns 25,000 shares in the company, valued at $100,750. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Stanley C. Erck sold 21,607 shares of the firm’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $3.71, for a total value of $80,161.97. Following the completion of the transaction, the director now owns 269,118 shares in the company, valued at approximately $998,427.78. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 89,381 shares of company stock worth $361,678 over the last 90 days. Insiders own 3.00% of the company’s stock.

MaxCyte Trading Up 1.4 %

Shares of MXCT stock opened at $3.67 on Friday. The firm has a market capitalization of $384.70 million, a price-to-earnings ratio of -10.49 and a beta of 1.39. The firm’s 50 day moving average is $4.11 and its 200-day moving average is $4.25. MaxCyte, Inc. has a 1 year low of $2.45 and a 1 year high of $5.55.

MaxCyte (NASDAQ:MXCT) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.05. The firm had revenue of $10.43 million for the quarter, compared to analyst estimates of $8.20 million. MaxCyte had a negative return on equity of 15.52% and a negative net margin of 77.97%. During the same period last year, the company earned ($0.10) EPS. On average, equities research analysts forecast that MaxCyte, Inc. will post -0.44 earnings per share for the current fiscal year.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.